Early Diagnosis of Lung Cancer in the United Arab Emirates: Challenges and Strategic Recommendations

被引:3
作者
Al-Shamsi, Humaid O. [1 ,2 ,3 ,4 ]
Jaffar, Hassan [5 ]
Mahboub, Bassam [6 ]
Khan, Faraz [7 ]
Albastaki, Usama [6 ]
Hammad, Sayed [8 ]
Al Zaabi, Ashraf [9 ]
机构
[1] Burjeel Canc Inst, Dept Oncol, Burjeel Med City, Abu Dhabi 111499, U Arab Emirates
[2] Burjeel Med City, Burjeel Canc Inst, Innovat & Res Ctr, Abu Dhabi 111499, U Arab Emirates
[3] Univ Sharjah, Coll Med, Sharjah 999041, U Arab Emirates
[4] Emirates Oncol Soc, Dubai 22107, U Arab Emirates
[5] Sheikh Khalifa Specialty Hosp, Ras Alkhaima 111499, U Arab Emirates
[6] Rashid Hosp, Dubai 111499, U Arab Emirates
[7] Amer Hosp, Dubai 111499, U Arab Emirates
[8] Dubai Hosp, Dubai 111499, U Arab Emirates
[9] Zayed Mil Hosp, Abu Dhabi 111499, U Arab Emirates
关键词
lung cancer; United Arab Emirates; screening; referral pathway; GUIDELINE; MUTATION;
D O I
10.3390/clinpract11030082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the United Arab Emirates (UAE), lung cancer (LC) was the third leading cause of deaths due to cancer in 2017. Around 80% of the patients in the UAE are diagnosed at a late stage, rendering the treatment less effective in improving survival outcomes. Lack of awareness of disease symptomatology, deficient screening initiatives, misdiagnosis, and delayed referral to the specialist are contributing factors for delayed diagnosis. Effective screening at a primary care setting can be crucial for early diagnosis, referral to specialists, and enhancing patient outcomes. It is important to establish screening and referral guidelines through which each suspected case can be identified and provided timely intervention. Although the international screening and referral pathway framework are comprehensive, several regional barriers need to be addressed before they can be adapted at the national level. A group of LC experts from the UAE deliberated on issues like delayed diagnosis of LC and strategic recommendations for overcoming the challenges. The discussion was based on the review of the published evidence, international and regional guidelines for screening and early diagnosis of LC. Herein, we present a guideline, endorsed by the esteemed panel of experts, for aiding early diagnosis and optimizing the management of LC in the UAE.
引用
收藏
页码:671 / 678
页数:8
相关论文
共 29 条
[1]   Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].
Aberle, Denise R. ;
Adams, Amanda M. ;
Berg, Christine D. ;
Black, William C. ;
Clapp, Jonathan D. ;
Fagerstrom, Richard M. ;
Gareen, Ilana F. ;
Gatsonis, Constantine ;
Marcus, Pamela M. ;
Sicks, JoRean D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409
[2]  
Al-Shamsi Humaid, 2020, Gulf J Oncolog, V1, P71
[3]  
[Anonymous], 2018, VAST MAJ HEAV SMOK N
[4]  
[Anonymous], 2020, REPORT LUNG CANC SCR
[5]  
[Anonymous], 2018, DOH LUNG CANC SCREEN
[6]  
[Anonymous], Lung Health Checks
[7]  
Del Giudice ME, 2014, CAN FAM PHYSICIAN, V60, P711
[8]   Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment [J].
Duma, Narjust ;
Santana-Davila, Rafael ;
Molina, Julian R. .
MAYO CLINIC PROCEEDINGS, 2019, 94 (08) :1623-1640
[9]   The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries [J].
Edelman Saul, Eduardo ;
Guerra, Raquel B. ;
Edelman Saul, Michelle ;
Lopes da Silva, Laercio ;
Aleixo, Gabriel F. P. ;
Matuda, Raquel M. K. ;
Lopes, Gilberto .
NATURE CANCER, 2020, 1 (12) :1140-1152
[10]  
Hassan J, 2020, J Cancer Prev Curr Res, V11, P130, DOI [10.15406/jcpcr.2020.11.00440, DOI 10.15406/JCPCR.2020.11.00440]